Amneal Pharmaceuticals, Inc. (AMRX) Stock Score, Valuation & Financial Research
Amneal Pharmaceuticals, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for AMRX
Amneal Pharmaceuticals, Inc. currently has a Wall Street Score of 26/100. The stored market price is $17.01. Its financial score is 22/100. Its valuation score is 10/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Amneal Pharmaceuticals, Inc. does
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, mar
AMRX financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $17.01
- Market capitalization:
- $5.43B
- Revenue:
- $3.12B
- Net income:
- $157.4M
- Free cash flow:
- $269.9M
- Cash:
- $127.6M
- Total debt:
- $2.79B
- EPS:
- 0.50
- P/E ratio:
- 34.2x
- Financial score:
- 22/100
- Valuation score:
- 10/100
- Revenue score:
- 24/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $269.9M, showing positive cash generation.
- The balance sheet shows $127.6M of cash versus $2.79B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.2 points: AMRX increased 0.2 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AMRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.